The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
The Drug Monitoring, Propoxyphene, Screen, Urine test contains 1 test with 1 biomarker.
Drug Monitoring, Propoxyphene, Screen, Urine
Clinical Significance
Drug Monitoring, Propoxyphene, Screen, Urine - d-Propoxyphene is a narcotic analgesic that is structurally related to methadone. The l-isomer is devoid of narcotic effects and is available as an antitussive. The FDA mandated the removal of propoxyphene products used for pain management in 2010. The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Therapeutic urine drug monitoring of propoxyphene is important for ensuring compliance to treatment strategies. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative.
Includes
If you require medMATCH for this order code, you must also order code 39158 - Prescribed Drugs, medMATCH®. If 39158 is ordered, all Drug Monitoring order codes will be treated as medMATCH.
If this test code is not ordered with 39158, all medMATCH result codes will be DNR’d.
Reference Range(s)
Propoxyphene <300 ng/mL
Alternative Name(s)
Prescription Drug Monitoring,Pain Management